Clinical Trial: Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease
Brief Summary: To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment
Detailed Summary:
Sponsor: ACADIA Pharmaceuticals Inc.
Current Primary Outcome: Cohen-Mansfield Agitation Inventory (CMAI) [ Time Frame: Approximately 12 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: ACADIA Pharmaceuticals Inc.
Dates:
Date Received: December 12, 2016
Date Started: November 2016
Date Completion: July 2019
Last Updated: April 18, 2017
Last Verified: April 2017